Such complex controls on the TGF-β1 network appear necessary to appropriately titrate the initiation, amplitude and duration of TGF-β1 pathway involvement in the tumor suppressor vs. pro-tumorigenic genomic programs. The gene discussed is TGFB1; the disease is neoplasm.